Biosimilars and implications for pharmacy practice: Ready or not, here they come! | Zendy

Joshua P. Crawford | Zendy; Andrea L. Hobbs | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biosimilars and implications for pharmacy practice: Ready or not, here they come!

Author(s) -

Joshua P. Crawford,

Andrea L. Hobbs

Publication year - 2019

Publication title -

pharmacy practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.608

H-Index - 24

eISSN - 1886-3655

pISSN - 1885-642X

DOI - 10.18549/pharmpract.2019.3.1659

Subject(s) - pharmacy , pharmacy practice , pharmaconomist , medicine , clinical pharmacy , health care , scope (computer science) , biosimilar , medical education , pharmaceutical care , promotion (chess) , informatics , nursing , family medicine , political science , politics , law , computer science , programming language

Biotechnology, the drug manufacturing strategy that has transformed the healthcare industry over the past 30 years, continues to produce novel, life-saving products. Monoclonal antibodies, biologic response modifiers, and cellular therapies have improved patient outcomes in many debilitating disease-states including hepatitis, cancer, autoimmune and inflammatory diseases. These innovative biologic medications are allowing patients to live longer, healthier lives, and pharmaceutical companies have shifted their focus to the production of these agents to meet the demands of a changing therapeutic landscape.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research